Quest Diagnostics Engager

Join our Engager Panel to Learn How You Can Leverage MRD in your Drug Development and Therapy Commercialization Strategies

Quest-Diagnostics-Symbol

Quest Diagnostics Engager

Wednesday 6th September 2023

6:00 pm Opening Remarks

6:15 pm Panel Discussion: ctDNA Analysis has the Potential to Provide High-Definition Insights in Drug Development

  • Dan Edelstein Chief Executive Officer, Haystack Oncology
  • Mark Gardner Senior Vice President, Molecular Genomics & Oncology, Quest Diagnostics
  • Greg Baschkopf Senior Director, In Vitro Diagnostics & Innovation, Quest Diagnostics

Synopsis

  • Stratify patients for trials  
  • Identify therapy response and resistance
  • Quantifiably track variants
  • Assess treatment outcome early

6:40 pm Interactive Q&A

6:55 pm Networking

7:30 pm End of Pre-Conference Day Two

REGISTER INTEREST HERE